Clinical Takeaway
In this small pilot trial, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time in adults with diagnosed insomnia disorder, suggesting that this cannabinoid combination did not improve and may have worsened objective sleep duration. These findings highlight that patient-reported improvements in sleep with cannabinoids do not always align with measurable changes in sleep architecture captured by high-density EEG. Clinicians should counsel insomnia patients that the evidence for cannabinoids as sleep aids remains preliminary and that objective outcomes may differ meaningfully from subjective experience.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides objective EEG-based evidence of how THC/CBD combinations affect sleep architecture and daytime function in patients with diagnosed insomnia disorder, filling a critical gap between widespread clinical use and limited mechanistic data. High-density EEG methodology enables precise characterization of cannabinoid effects on sleep stage dynamics and cortical activity, informing dosing strategies and patient selection for cannabinoid-based sleep interventions. These findings are essential for evidence-based integration of cannabinoids into insomnia treatment algorithms and for identifying potential safety concerns regarding next-day cognitive impairment.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study adds valuable objective neurophysiological data to the cannabis-insomnia conversation, using high-density EEG to move beyond subjective sleep reports in a small insomnia cohort. The 10:200 THC:CBD ratio and single-dose design are notable limitations, as clinical cannabis use for sleep often involves different ratios, repeated dosing, and longer treatment periods, making it difficult to extrapolate findings to real-world prescribing. The predominance of female participants and small sample size further restrict generalizability, and we should note the absence of next-day functional assessments in the abstract provided, which is critical given that some patients report morning grogginess with cannabinoids. That said, the methodological rigor of high-density EEG provides mechanistic insights that can inform hypothesis generation for larger, longer-duration trials. Clinically, this work suggests we should remain cautious about recommending cannabinoids as first-line sleep agents while acknowledging patient interest; if considering them
| |